Agoraphobia (AG) is undeniable, yet the crucial task of elucidating the mechanisms of action lags behind. Far from an abstract theoretical concern, understanding the mechanisms of action of treatment would provide knowledge on how to generalize the principles utilized in treatment studies and offer hope for the sizable minority of patients that do not respond to current treatments (Hofmann & Smits, 2008) by amplifying those specific processes known to affect outcome. Towards this aim, conceptual and methodological clarity are crucial.
Much theoretical and empirical work has been devoted to explaining the nature and treatment of PD and AG. Cognitive accounts suggest that catastrophic misinterpretation of bodily sensations influences the etiology and maintenance of PD and AG (Clark, 1986) .
Cognitive therapy thus targets the content and frequency of associated thoughts through numerous methods. Anxiety Sensitivity, or the fear of anxiety and fear, has also been conceptualized as a risk factor associated with the subsequent onset of panic disorder (Ehlers, 1995) , and with avoidance behaviors (Zvolensky & Forsyth, 2002) . Anxiety sensitivity is consequently considered an important therapeutic target for PD/AG (Smits, Powers, Cho, & Telch, 2004) achieved through various means including interoceptive exposure. However, the pernicious effects of both cognitive appraisals and anxiety sensitivity depend in part on how an individual attempts to regulate their negative affect (Kashdan, Zvolensky, McLeish, 2008) .
This suggests that successful therapy must also target the way one interacts with these negative appraisals, beliefs, and emotions.
A common regulation strategy for these negative appraisals and emotions is avoidance. Indeed, agoraphobic avoidance, or the avoidance of feared situations, is a defining feature of agoraphobia (Chambless, Caputo, Jasin, Gracely, & Williams, 1985) even in the absence of PD (Wittchen et al., 2008; Wittchen, Gloster, Beesdo-Baum, Fava, & Craske, 2010) . Although not always explicitly targeted (Hofmann & Spiegel, 1999) , reduction of agoraphobic avoidance is a common therapeutic target and is associated with successful outcome . Another regulatory strategy recently implicated in PD/AG is psychological flexibility. Psychological flexibility refers to the ability to mindfully accept cognitions and emotions when doing so is useful for living a meaningful life (Bond et al., 2011) . Similar to anxiety sensitivity, psychological flexibility is not exclusively relevant to PD/AG, yet has been implicated in panic-related distress (Karekla, Forsyth, & Kelly, 2004) , baseline functioning in anxiety disorders (Gloster, Klotsche, Chaker, Hummel, & Hoyer, 2011) , treatment outcome (Forman, Herbert, Moitra, Yeomans, & Geller, 2007) , and is conceptually distinct from anxiety sensitivity in patients with PD/AG (Kämpfe et al., 2012) .
Given that appraisal of anxiety symptoms, anxiety sensitivity, avoidance, and psychological flexibility are all associated with various aspects of PD/AG, it is important to understand to what degree some or all these constructs are active mechanisms for successful treatment outcome. Mediation analysis (Baron & Kenny, 1986 ) has emerged as one important analytical procedure for the critical testing of putative mechanisms of action in therapy (Kazdin, 2007) and a handful of formal mediation analyses have been conducted across variations of CBT for PD/AG (e.g., group vs. individual therapy). These studies provide positive evidence for the mediating or partially mediating role of cognitive content, cognitive appraisal, and self-efficacy (Casey, Newcombe, & Oei, 2005; Hofmann et al., 2007 , Meulenbeek, Spinhoven, Smit, Van Balkom, & Cuijpers, 2010 Vögele et al., 2010) and anxiety sensitivity (Smits, Powers, Cho, & Telch, 2004) in reducing the severity of panic disorder. Although an important step towards isolating active mechanisms, these findings are limited by the fact that the assessment of target variables did not precede outcome assessments. That is, the process variables were tested concurrently with the outcome measure (e.g., both measured pre -post). This lack of temporal order hinders interpretation because it is unclear if the outcome variables also influence the process variables and because such designs leave open the possibility that process variables exert their effects at different points during the therapy.
Longitudinal temporal testing of putative mechanisms within the course of treatment for PD/AG has been examined only in a few studies. In one such study, 12 patients diagnosed with PD/AG completed daily diaries for 30 weeks (Bouchard et al., 2007) . CBT was administered in groups and emphasized either cognitive or exposure interventions. Daily dairies were used to assess beliefs about the consequences of panic, self-efficacy to control panic attacks in the face of bodily sensations and catastrophic thoughts, and anticipatory anxiety about having a panic attack that day. During the course of therapy, all 12 patients recorded changes in their beliefs and level of self-efficacy prior to recording changes in anticipatory anxiety, irrespective of condition. Despite the small sample size, this study demonstrated with temporal sensitivity that changes in cognitive variables preceded change in other aspects of symptomatology for all patients, though the magnitude of change differed across patients.
To our knowledge, only a few further studies temporally examined whether salient process variables preceded subsequent change in panic-related outcomes. Using cognitive therapy and guided mastery -both administered in a group format - Hoffart (1995) examined the relevance of self-efficacy, catastrophic beliefs, and perceived control of thoughts on subsequent fear in a behavioral avoidance test (BAT). Results from the 46 patients included in the study indicated that change in self-efficacy was the strongest and most consistent predictor of subsequent change in fear during the BAT. A second study (Teachman, Marker, & Clerkin, 2010) examined whether catastrophic misinterpretations subsequently affected various facets of panic symptomatology. Panic control treatment was administered in a group format to 43 patients. Using bivariate difference score modeling analysis, results indicated that change in catastrophic misinterpretation predicted subsequent change in panic symptomatology. The reverse pattern (i.e., symptomatology predicting subsequent change in catastrophic misinterpretation) was not consistently found except for distress/ apprehension.
A final study examined cognitive process variables during the first phase of treatment (i.e., four weeks) in 41 patients diagnosed with PD/AG (Meuret, Rosenfield, Seidel, Bhaskara, & Hofmann, 2010) across two distinct treatment conditions. Process variables were operationalized as a composite score of questionnaires that measure anxiety sensitivity/ fear about the consequences of panic (i.e., anxiety sensitivity index (ASI) and body sensation questionnaire (BSQ), respectively) in addition to perceived control. During the phase of treatment examined, patients received either cognitive treatment or capnometry-assisted respiratory training. So designed, the specificity of the cognitive process variables could be tested across relatively pure intervention conditions. Indeed, results suggested that cognitions were bidirectionally associated with changes in panic severity only in the cognitive training condition whereas perceived control was bidirectionally associated with panic symptom change in both conditions. This excellent study included information only from the first half of treatment (four weeks), however, thus limiting information about how mechanisms unfold over the full course of treatment or generalize following treatment. Taken together, these studies provide strong support for the role of cognitively oriented process variables defined as catastrophic misinterpretations and self-efficacy in the prediction of subsequent change in symptomatology.
To our knowledge, no other PD/AG relevant process variables than those discussed above (i.e., feared consequences / anxiety sensitivity and self-efficacy/ perceived control to cope with panic) have been tested. Examination and direct comparison of other variables implicated in the treatment of PD/AG such as avoidance behavior and psychological flexibility is a crucial step in the process of understanding the mechanisms of treatment (Kazdin, 2007) .
In addition to expanding the scope of process variables under investigation, outcome variables also need to be expanded. To date, all process studies examined the effect on panicrelated variables, but only one examined how putative mechanims affect other outcomes such as functioning (Smits et al., 2004) . It remains an open question whether the mechanisms of action involved in symptom reduction are identical in importance and sequence to those involved in other treatment targets. Social, occupational, and psychological functioning are certainly related to symptomatology, yet it is a broader measuring stick. Indeed, the impetus for patients to seek therapy may be primarily related to functioning and in our quest to better understand mechanisms care should be taken not to reduce patients to their symptomatology.
This purpose of the present study was to investigate the degree to which five process variables affect treatment outcome across the active and follow-up phases of a standardized CBT for PD/AG. Towards this end, the process variables were examined across phases of therapy for two outcomes: severity of PD/AG symptomatology and overall functioning. The process variables were examined longitudinally using bivariate latent difference score modeling to determine the relative effects of the process variables at different points in the therapeutic process. So doing, the relative importance of the process variables were examined for their relationship to different components of the therapy. We hypothesized that the variables would differentially predict subsequent symptoms as a function of treatment phase 
Methods

Design
Data were collected within the Mechanisms of Action for CBT (MAC) study. The MAC study was a multicenter, randomized controlled trial for patients with PD/AG. The methods and main outcomes of the study were published elsewhere (Gloster et al., 2009; . The MAC study was approved by the internal review board of all relevant institutions. The current study included all patients (n =369), but the longitudinal analyses were limited only to those patients who received treatment (n = 301). Thus, the n = 68 waitlist patients were excluded from this set of analyses.
Participants
All patients met Diagnostic and Statistical Manual of Mental Disorders (4 th ed., text rev.; DSM-IV-TR; American Psychiatric Association, 2000) diagnostic criteria for PD with AG, scored ≥18 on the Hamilton Anxiety Scale (HAM-A), and ≥4 on the Clinical Global Impression Scale (CGI). Other current comorbid diagnoses, including unipolar depression and other anxiety disorders, were allowed unless they were of primary clinical concern. Over 90% of the sample had at least one comorbid condition, with nearly half the sample diagnosed with two or more mental disorders in addition to PD/AG. The most frequent comorbid conditions were specific phobia (n = 214; 71.1%), harmful use/abuse of alcohol (n = 135; 44.9%), social phobia (n = 126; 42.4%), and major depression (n = 118; 39.2%). As such, this sample can be considered both relatively severe and representative of patients seen in clinical practice. All patients were free from psychopharmacological medication. Extensive details about inclusion and exclusion criteria have been previously published (Gloster et al., 2009; .
The 301 patients in this study had a mean age of 35.5 (10.7). A majority of patients were women (n = 228, 75.8%) and 131 (43.5%) had at least some higher education. Nearly a third were married (n = 98, 32.7%), half were single (n = 165, 55.0%), and the rest were divorced or widowed. Consistent with the demographic characteristics of the population from which these data were sampled, all participants were of Caucasian origin.
Treatment
Patients received a 12-session manualized treatment protocol (Lang, Helbig-Lang, Westphal, Gloster, & Wittchen, 2011) , implemented over 6 weeks, and followed by two booster sessions. Sixty-three certified therapists, all of whom were either advanced graduate students or post-docs, administered treatment. All therapists went through a thorough training and certification procedure. Treatment integrity, training, randomization, and further design issues are published elsewhere .
The treatment was highly efficacious and consisted of three 
Assessment
Measures were assessed pre-treatment, at the intermediate point in treatment (between the 4 th and 5 th sessions), post-treatment (after the 12 th session), and at the 6-month follow-up, which occurred 6 months after the post-treatment assessment. The one exception is the anxiety sensitivity index, which was not measured at the intermediate assessment.
PD/AG symptomatology and clinical functioning.
Panic and Agoraphobia Scale (PAS; Bandelow, 1997).
The PAS is a patient selfreport, 13-item questionnaire that measures the severity of panic attacks, avoidance, anticipatory anxiety, disability, and worries about health. All items are scored from 0 to 4.
Scores on the PAS have have good reliability and are sensitive to change (Bandelow, 1997; . The internal consistency of the PAS in this sample was α = 0.86.
Clinical Global Impression Scale -Severity Subscale -Functioning Item (CGI;
Guy, 1976). CGI is a clinician-rated scale that measures the overall severity of a disorder, with scores that range between 1 (no disorder) and 7 (among the most severely ill patients).
The scale normally queries for information across the facets of panic symptoms, anxiety, anticipatory anxiety, avoidance, and overall functional level before making the global rating.
Scores on the CGI are sensitive to change in panic treatment (Barlow et al., 2000; . For this study we only used the one item measuring overall functioning in order to maximize conceptual distinctness from the PAS.
Process Variables.
Agoraphobic Cognitions Questionnaire (ACQ; Chambless, Caputo, Bright, & Gallagher, 1984). The ACQ is a 14-item self-report questionnaire that measures the frequency of catastrophic beliefs about the possible consequences of experienced anxiety and panic. Each item is rated on a five-point scale, ranging from 1 (never) to 5 (always). The ACQ has sound psychometrics and is a standard assessment in PD/AG research (Zgourides, Warren, & Englert, 1989) . The internal consistency of the ACQ in this sample was α = 0.74.
Bodily Sensations Questionnaire (BSQ; Chambless et al., 1984).The BSQ is a 17
item self-report questionnaire that measures the degree of anxiety elicited by body sensations.
Each item is rated on a five-point scale, ranging from 1 (not at all) to 5 (extremely). The BSQ has sound psychometrics and is a standard assessment in PD/AG research (Zgourides, Warren, & Englert, 1989) . The internal consistency of the BSQ in this sample was α = 0.87.
Mobility Inventory (MI; Chambless, Caputo, Jasin, Gracely, & Williams, 1985). The
MI is a self-report questionnaire that measures the degree to which 27 situations are avoided.
Items are scored from 1 (never avoid the situation) to 5 (always avoid the situation), with the mean of all items as the total score. Scores of the MI are highly reliable and sensitive to change (Chambless et al., 1985; . For this study, only the ratings for the "alone" subscale are utilized. The internal consistency of the MI in this sample was α = 0.93. 
Anxiety Sensitivity
Acceptance and Action Questionnaire -II (AAQ-II;Bond et al., in press
). The AAQ-II is a 7-item self-report questionnaire that measures psychological flexibility. Each item is rated on a seven-point scale from 1 (never true) to 7 (always true). The AAQ-II has demonstrated sound psychometrics and is associated with various indices of PD/AG and other anxiety disorders, with good discriminant validity (Bond et al, 2011; .
The internal consistency of the AAQ-II in this sample was α = 0.94.
Statistical Analyses
Lower level mediation analyses were conducted to investigate the association of the five process variables ACQ, BSQ, MI, ASI, AAQ-II and the change in treatment outcomes PAS and CGI over time (Kenny, Korchmaros, & Bolger, 2003) as a preliminary step in data analyses. The associations were estimated by Multilevel linear mixed models with time as predictor variable, the five process variables ACQ, BSQ, MI, ASI and AAQ-II as time varying covariates and PAS and CGI as outcomes (Kenny, Korchmaros, & Bolger, 2003; Singer & Willet, 2003) .
Latent difference score (LDS) models provide a tool where change and individual differences in change are represented in the model (Selig & Preacher, 2009 ). LDS incorporates features of latent growth curve modeling and cross-lagged regression models.
We only shortly describe our analytic strategy, a detailed presentation of the theory can be found in McArdle & Nesselroade (1994) or Hawley, Ho, Zuroff & Blatt (2006) . We evaluated different univariate LDS models for the change of PAS, CGI, ACQ, BSQ, ASI, AAG-II and MI over time for investigating the nature of change in a first step. The latent change in a repeatedly observed score Y in an individual n at time t can be expressed by Δ y(t)n = y(t)n -y(t-1)n = αy syn + βy y(t-1)n, 1
where the observed score Y(t)n can be decomposed into a true score y(t)n and a measurement error en with a mean of zero and a positive variance. The latent change in Y is the sum of two components in equation (1), an additive (αn syn) and a proportional (βy y(t-1)n) change component. The coefficient syn corresponds to an intercept in the equation, which may vary across individuals and is constant over time. The α coefficient is a factor loading and fixed to one for model identification purposes. The coefficient βy represents the proportional effect of the previous latent variable on the change rate. We compared univariate LDS models for time-invariant and time-varying proportional coefficients βy as well as a no change score LDS model (Δ y(t)n = 0, αy = βy = 0 in equation 1) for each considered score. The univariate LDS models where combined to establish bivariate LDS in a second step. Bivariate LDS models provide an appealing feature for investigating whether one score is the leading indicator of change in the other variable. A coupling parameter γ is included into the equations of two univariate LDS models representing the effect of one score on the rate of change in the other.
The bivariate LDS model with an other score z(t) at time t can be written by Δ y(t)n = y(t)n -y(t-1)n = αy syn + βy y(t-1)n + γz z(t-1)n Δ z(t)n = z(t)n -z(t-1)n = αz szn + βz z(t-1)n + γy y(t-1)n.
2
The relationship between the two dual change LDS models is given by the components γz z(t-1)n and γy y(t-1)n besides the additive and proportional change components. The subsequent latent change in one variable is predicted by the other variable occuring earlier in time in case of coupling between the two univariate LDS models. We investigated different patterns of coupling between two univariate LDS models by restricting the path coefficients in the models. The analyses included models with (i) no coupling (γz = 0 and γy = 0) between the two series, (ii) unidirectional coupling exists in which one variables predicts later change in the other and vice versa (γz = 0 and γy ≠ 0 or γz ≠ 0 and γy = 0) and (iii) bidirectional coupling exists between the two scores (γz ≠ 0 and γy ≠ 0). We also compared models with timeinvariant and time-varying coupling coefficients γz and γy. Whenever the final model indicated that more than one γ coefficent (one per phase of treatment) per process variable was significant, the ceofficencts were tested for significant differences. The third step of our analyses concerns the hypotheses whether treatment condition (T+ vs. T-) predicts the subsequent rate of change in the studied variables over the treatment process. Treatment condition is added by the term (φ TX) in the equations 2. All path coefficients are reported as unstandardized coefficients. The parameters of the LDS models were estimated in Mplus version 6.1 (Muthen & Muthen, 2007) . We used the full the full-information maximum likelihood estimator due to missing data in some cases. This approach ensures the use of all available data for parameter estimation. Thus, also patients with incomplete sessions were incorporated into analyses.
Results
Baseline Values
The mean and standard deviations for the outcome variables and process variables at baseline and post-treatment are displayed in Table 1 . The correlations between variables at baseline and post-treatment are likewise displayed in Table 1 .
Lower level mediation models
The association of the five process variables ACQ, BSQ, ASI, MI, AAQ-II and the treatment outcomes PAS and CGI were investigated by lower level mediation models. This preliminary step was conducted in view of the existing literature. ACQ, BSQ, MI, ASI and AAQ-II all partially mediated the treatment outcomes of PAS and CGI as indicated by a significant mediated effect in the mediator analyses (available upon request). However, lower level mediation models are inadequate to show sequencing across time.
The WL reported only negligible pre-treatment to post-treatment changes and was significantly worse than both treatment groups at post-treatment (see .
Nevertheless, the WL was tested here using lower-level models. As expected, the WL group did not demonstrate any meditational effects. As no meaningful change was observed in this group, predicting change was not possible and this group was excluded from further longitudinal analyses below.
Univariate Latent Difference Score Models
The change in PAS, CGI, ACQ, BSQ, MI, ASI and AAQ-II was investigated by univariate LDS models including the no change model and the two dual change models with both time-varying and time-invariant proportional effects β(t). The no change LDS models consistently resulted in a poor model fit (SRMR ranges form .26 for ASI to .42 for AAQ-II).
The univariate LDS models including time-varying proportional effects β(t) substantially improved model fit compared to time-invariant proportional effects in all analyzed models. 
Discussion
This study examined the mechanism of action in CBT for Panic Disorder with Agoraphobia using temporally sensitive bivariate latent difference score modeling in a large sample of 301 patients. Importantly, the current study found evidence for the temporal specificity of process-outcome effects over the course of therapy and differences between outcome measures. Change in a comprehensive measure of panic and agoraphobic symptoms did not predict subsequent change in functioning at any point during the study.
Taken together, our hypotheses were partially supported. In partial contrast to our hypothesis, cognitive appraisal predicted subsequent change in panic and agoraphobia symptoms across all time points and not just during sessions 1-4. Consistent with our hypothesis, cognitive appraisal did not predict subsequent change in functioning. Contrary to our hypothesis, anxiety elicited by bodily symptoms did not predict subsequent change in panic symptoms at any time point and did predict subsequent functioning at the follow up assessment. Contrary to our hypothesis, anxiety sensitivity predicted subsequent panic and agoraphobia symptoms only during the follow-up period. However, consistent with our hypothesis, anxiety sensitivity was related to functioning during the treatment phase.
Consistent with our hypotheses, avoidance behavior was related to subsequent change in panic symptoms and functioning across all phases. Also consistent with our hypothesis, psychological flexibility predicted subsequent change in panic symptoms during sessions 5-12
and functioning across all time points. This research builds on previous studies, all of which used panic and/ or agoraphobic symptoms as an outcome variable. Although some of these studies largely lacked prospective temporal designs that measured process variables and outcome measures longitudinally (see Meuret et al., 2010 , Teachman et al., 2010 for exceptions), results from these studies help piece together the puzzle of the processes relevant for effective treatment. Indeed, our results are consistent with the reliable finding that measures of one's appraisal of symptoms (e.g., ACQ, BSQ, and ASI) mediated or partially mediated outcome (Casey et al., 2005; Smits et al., 2004; Meuret et al., 2010; Hofmann et al., 2007; Voegele et al., 2010; Meulenbeek et al., 2010) . This finding was also found in studies that used different analytical frameworks such as time series analysis (Bouchard et al., 2007) structural equation modeling (Hoffart, Sexton, Hedley, & Martinsen, 2008) , and bivariate latent difference score modeling (Teachman, Marker, & Clerkin, 2010) .
The longitudinal analysis used in the current study advance our understanding of when and to some degree how the consistent finding that one's appraisals of panic and agoraphobic symptoms mediates outcome. Consistent with previous studies, results of the current study suggest that panic symptomatology is affected by one's catastrophic beliefs (ACQ) during all phases of treatment. These analyses also suggest that this effect is strongest during the generalization phase. Similarly, agoraphobic avoidance is associated with subsequent change in PAS across treatment. Interestingly, psychological flexibility seems to affect panic symptomatology during the in situ exposure phase of treatment. This would suggest that exposure in situ requires a patient to engage with the feared stimuli in a flexible manner and take steps to reduce avoidance behavior (see Gloster et al., 2012) . During the follow-up period, agoraphobic avoidance, catastrophic cognitions, and fear of fear are the salient process variables. In sum, whereas cognitive variables do affect panic and agoraphobic-related outcome, the present results suggest that not all cognitive variables predict outcome, and which cognitive variables are the most salient predictors depends on the phase of treatment.
However, given their exploratory nature these findings clearly require replication before firm conclusions can be drawn.
We also found evidence for the process of change in two variables not previously tested. First, the degree of self-reported situational agoraphobic avoidance (MI) was most consistently associated with the reduction in panic and agoraphobic symptoms and functioning. The bidirectional relation suggests a complex relation between these variables, likely due in part to a partial overlap of the constructs. It is important to note that two previous mediation studies included agoraphobic avoidance in their analyses but treated it as a dependent variable (Vögele et al, 2010; Meulenbeek et al., 2010) . We treated agoraphobic avoidance as a potential process variable, however, because the treatment conceptualized avoidance and safety behaviors as a maintaining variable and directly targeted them (both those publically observable and those only observable to the patient). As such, the mobility inventory captured one class of this behavior. The final process variable associated with changes in the outcome was psychological flexibility (AAQ-II). This variable is not specific to panic and agoraphobia and the AAQ-II does not contain any words specifically referring to panic or agoraphobia. Instead, it is a broader construct that measures the degree to which one can mindfully accept thoughts and emotions while engaging in one's life when it is important to do so. As such, it is theoretically consistent that psychological flexibility was associated with change in panic and agoraphobia symptoms only during the phase of treatment that concentrated on exposure in situ but not the phase that concentrated on psychoeducation (Gloster, Hummel, Lydmirskya, Hauke, & Sonntag, 2012) : dropping subtle avoidance behaviors and mindfully accepting associated thoughts and emotions promotes change. It is likewise theoretically consistent that psychological flexibility was consistently related to subsequent change in functioning: promotion of psychological flexibility increases one's ability to engage with that which is important to the patient.
This study also expanded the examination of process variables on the outcome of global functioning. In addition to adding information about how the putative process variables affect a broader target, testing the process variables against the CGI also served as a test of specificity for the process variables. The variables associated with the change in global functioning were agoraphobic avoidance and psychological flexibility across all treatment phases; anxiety sensitivity during the active phase of treatment; and fear of bodily symptoms during the generalization phase of treatment. Interestingly, the cognitive appraisal process variables that have consistently been found to be associated with change in panic and agoraphobic symptoms were no longer significantly related to global functioning in the longitudinal models and only anxiety sensitivity was related to change in functioning during the active treatment phase. This, therefore, partially supports and is simultaneously in partial contrast to Smits et al., 2004, who Treatment group (T+ vs. T-) did not contribute to the explanation of relation between processes and outcome and were not included in the final models. This suggests that despite the slight advantage seen by the T+ group in outcome (Gloster et al., 2001) , both treatment variants seem to work through the same processes. This is not surprising as both treatment variants had identical content and differed only with respect to the therapist's presence during exposure in situ. It remains a possibility that the presence of the therapist may have facilitated the dropping of safety behaviors or offered more intense guidance, but the sum total of such effects -if they do indeed exist -are not strong enough to be detected by these analyses.
By linking process-outcome effects with specific phases and elements of treatment, we are in a stronger position to tie together results from outcome trials with current theories about the mechanisms that underlie treatment. For example, inhibitory learning that promotes tolerance of anxiety and develops competing non-threat expectancies and that can be generalized across contexts is believed to be a crucial mechanism in exposure therapy (Arch & Craske, 2008) . This study, then, shows with temporal fidelity that some of the therapeutic This study needs to be interpreted in the light of several limitations. First, although consistent with previous studies, the process variables examined in this study were assessed using questionnaires are limited by the retrospective recall bias inherent in questionnaires.
Future studies using additional methodologies (e.g., ecological momentary assessment, physiological variables, etc.; e.g., Domschke et al., 2010; Kircher et al., in press; Richter et al., in press) , with different sources of method variance are clearly needed. Second, although we broke down the effects of time across our treatment, the effects of time and the treatment components that occurred during that period of the treatment cannot be parceled apart. Third, the ASI was not administered during the intermediate assessment. Further, the original ASI was utilized in this study. Subsequent versions of the ASI have expanded the measure and emphasized its multidimensional aspects (Taylor & Cox, 1998; Taylor et al., 2007) . Although all versions of the ASI target the overarching concept of anxiety sensitivity, results from this study do not inform about dimensions of anxiety sensitivity as accentuated in more recent versions of the ASI. Likewise, these results cannot speak to the taxonic structure of the ASI.
Fourth, although agoraphobic avoidance was revealed to be of core relevance in these analyses, other subtle aspects of avoidance such as cognitive avoidance, utilization of safety signals, etc. were not specifically assessed and therefore the relevance of these and other unassessed factors could not be modeled. Fifth, the examined process variables as well as the outcome variables are not without overlap. Whereas this not unique to this study, construct overlap is extremely difficult to avoid in psychological research. To test the robustness of these results, we modeled several variations (i.e., with and without inclusion of the avoidance subscale on the PAS) and did not find any noticeable affect on the pattern of results. Sixth, it should be noted that not even sophisticated statistical analyses such as bivariate latent difference score modeling can establish the theoretical concepts, processes, and theories under investigation. Instead, statistical analysis is one approach to examining the process-outcome relations (Kenny, Korchmaros, & Bolger, 2003; McArdle & Nesselroade, 1994) . Finally, although the study from which these data are derived was partly designed to facilitate these types of analyses (i.e., assessment strategy) and had significantly more power than previous studies, the study did not randomize across the theoretical concepts under consideration. As such, the results should be considered post-hoc in nature and appropriate caution should be used in their interpretation.
Using bivariate latent difference score modeling, this study contributed to the understanding of processes underlying treatment in several ways. First, we replicated the importance of attribution variables consistently implicated in the process-outcome relationships in previous studies. Second, we expanded the list of process variables to agoraphobic avoidance and psychological flexibility. Third, we found clear evidence for the differentiation of meditational effects across outcomes (symptomatology vs. functioning).
Finally, and most importantly, we found evidence that putative process variables are associated with changes in outcomes differently at different stages in the treatment. Increasing the time resolution under investigation allows for a better understanding of how processes unfold over time by overcoming a limitation of cross-sectional data. Namely, that they leave open the possibility that multiple constructs are relevant, but that they exert their effect at different points of time during therapy. The results in this study and similar studies have the potential to augment the effects of our current treatment and help therapists better deliver the treatments. The results point to specific processes at work and the timing of these processes.
If substantiated within and across disorders, results like these may help the sizeable minority of patients who do not respond (Hofmann & Smits, 2008) and/or potentially improve the long-term prospects of patients, which is currently unclear (Durham et al., 2005.) All correlations are significant at the 5% level; PAS = Panic Agoraphobia Scale; CGI = Clinical Global Impression; ACQ = Agoraphobic Cognitions Questionnaire ; BSQ = Bodily Sensations Questionnaire; ASI = Anxiety Sensitivity Inventory; MI = Mobility Inventory; AAQ-II = Acceptance and Action Questionnaire -II CGI = Clinical Global Impression; ACQ = Agoraphobic Cognitions Questionnaire; BSQ = Bodily Sensations Questionnaire; ASI = Anxiety Sensitivity Inventory; MI = Mobility Inventory; AAQ-II = Acceptance and Action Questionnaire -II; BIC = Bayesian information criterion, CFI = Comparative fit index, TLI = Tucker-Lewis index, RMSEA = Root mean square error of approximation; SRMR = standardized root mean square residual; # = number of model parameters; β1, β2 and β3 distinct time-varying proportional change coefficients; γ1,CGI_pv, γ2, CGI _pv, γ3, CGI _pv distinct coupling coefficients for latent PAS predicting later change in process variable; γ1,pv_ CGI, γ2, pv_ CGI, γ3, pv_ CGI distinct coupling coefficients for latent process variable predicting later change in PAS; -* indicates that the parameter is not estimated due to missing ASI at intermediate assessment;
